Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders

A compound of Formula (I) or a pharmaceutically acceptable salt thereof:

• wherein
• R1 is cyclopropyl, cyclobutyl, or 4-membered heterocyclyl, wherein R1 is optionally substituted with one or more groups selected from the group consisting of halo, alkyl, hydroxyalkyl, haloalkyl, and monoalkylaminoalkyl;
• R2 and R3 are independently —H, halo, alkyl, alkoxy, —CF3, —CHF2, —CH2F, or —OCF3;
• R4 is aryl, heteroaryl, cycloalkyl, heterocyclyl, or heteroalkyl, wherein R4 is optionally substituted with one or more groups selected from the group consisting of halo, hydroxyl, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, hydroxyalkyl, dialkylaminoalkyl, trimethylsilylethoxymethyl, —CH2NHC(O)CH3, —NO2, —NRaRb, —NRaC(═O)Rb, —NRaC(═O)NRaRb, —NRaC(═O)ORb, —ORa, —CN, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, —OC(═O)NRaRb, —SRa, azetidinyl, oxetanyl, tetrahydrofuranyl, furanyl, pyrrolidinyl, pyrrolyl, pyrazolyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furazanyl, oxadiazolyl, thiadiazolyl, phenyl, tetrahydropyranyl, pyranyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl;
• Ra and Rb are independently —H, halo, amino, alkyl, or haloalkyl;
• and
• R5 is H, halo, or alkyl.